Lecanemab and donanemab (Kisunla), another anti-amyloid treatment, won approval based on evidence that they slowed cognitive ...

A world-leading experimental dementia drug designed to prevent the disease before it begins will be trialled in Australia for ...

To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50 per cent more weight than those using rival Novo Nordisk's Wegovy.

The Food and Drug Administration's approval in 2023 of lecanemab—a novel Alzheimer's therapy shown in clinical trials to ...

In a recent study, researchers found adverse events were rare and manageable among clinic patients with very mild or mild Alzheimer's disease who received lecanemab infusions.

A new study has found that a common class of medications could dramatically decrease the risk of developing the neurodegenerative disorder.

In an executive order Monday morning, Trump announced plans to reduce drug prices by 30 to 80%.

Researchers found the PHGDH gene directly causes Alzheimer’s and discovered a drug-like molecule, NCT-503, that may help ...

Researchers have discovered how to block cells dying, in a finding that could lead to new treatments for neurodegenerative ...

The Food and Drug Administration's approval in 2023 of lecanemab - a novel Alzheimer's therapy shown in clinical trials to modestly slow disease progression - was met with enthusiasm by many in the ...

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.